This phase I trial will evaluate the safety and efficacy of additional peritoneal instillation of EpCAM CAR-T cells as compared to conventional chemotherapy alone in patients with EpCAM-positive GC-PC. This evidence concerns the gene EPCAM and pachyonychia congenita.